Administration
Erythropoiesis-stimulating agent (ESA) therapy:
- should not be initiated in the presence of absolute iron deficiency without also managing the iron deficiency
- in people with functional iron deficiency*, iron supplements should be given concurrently when initiating ESA therapy
- when correcting anaemia of CKD, the dose and frequency of ESA should be:
- determined by the duration of action and route of administration of the ESA
- adjusted to keep the rate of Hb increase between 1 and 2 g/dl/month
- ESA therapy and ACE inhibitors (or ARBs)
- if ACE inhibitors (or ARBs) are used, an increase in ESA therapy should be considered
- blood pressure rises transiently with administration.
The summary of product characteristics should be consulted before prescribing this drug.
Reference:
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.